Zurcher Kantonalbank Zurich Cantonalbank Sells 606 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,348 shares of the company’s stock after selling 606 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Kymera Therapeutics were worth $311,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Northern Trust Corp grew its stake in Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company’s stock worth $17,614,000 after purchasing an additional 53,658 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Kymera Therapeutics in the fourth quarter worth approximately $344,000. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company’s stock worth $183,000 after purchasing an additional 6,509 shares in the last quarter. Millennium Management LLC grew its stake in Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company’s stock worth $4,663,000 after purchasing an additional 77,912 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company’s stock worth $1,914,000 after purchasing an additional 5,771 shares in the last quarter.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several research analyst reports. BTIG Research reissued a “buy” rating and issued a $59.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Stifel Nicolaus initiated coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $55.00 target price on the stock. Bank of America raised Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 target price on the stock in a research report on Monday, June 2nd. Morgan Stanley initiated coverage on Kymera Therapeutics in a research report on Thursday, July 3rd. They set an “overweight” rating and a $70.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their target price on Kymera Therapeutics from $57.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday, June 3rd. Two research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics has an average rating of “Buy” and an average target price of $59.11.

Kymera Therapeutics Trading Down 0.6%

Shares of KYMR opened at $40.62 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $53.27. The stock has a fifty day moving average price of $45.11 and a 200-day moving average price of $36.58. The firm has a market cap of $2.65 billion, a PE ratio of -13.10 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.10. The firm had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The business’s revenue for the quarter was up 114.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.69) EPS. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il bought 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The stock was bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares of the company’s stock, valued at approximately $123,146,980. The trade was a 12.78% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Elena Ridloff sold 12,000 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total value of $553,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 over the last three months. Corporate insiders own 16.01% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.